<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0912211460
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NAPROTEX 500 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NAPROXEN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AE02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>What it does</u></strong></p><p>NAPROTEX (naproxen), which has been prescribed to you by your doctor, is one of a large group of non&ndash; steroidal anti&ndash;inflammatory drugs (also called NSAIDs). It is used to treat the symptoms of certain types of arthritis. It helps to relieve joint pain, swelling, stiffness and fever by reducing the production of certain substances (prostaglandins) and by helping to control inflammation.</p><p>&nbsp;</p><p><strong><u>What the medication is used for</u></strong></p><p>NSAIDs do not cure arthritis, but they promote suppression of the inflammation and the tissue damaging effects resulting from this inflammation. This medicine will help you only as long as you continue to take it.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- <u>Do not take NAPROTEX</u></strong></p><p>Before taking this medication tell your doctor and pharmacist if you:</p><ul><li>or a family member are allergic to or have had a reaction to naproxen or other anti-inflammatorydrugs (such as acetylsalicylic acid (ASA), diclofenac, diflunisal, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, mefenamic acid, naproxen sodium, piroxicam, tiaprofenic acid, tolmetin, nabumetone or tenoxicam) manifesting itself by increased sinusitis, hives, the initiating or worsening of asthma or anaphylaxis (sudden collapse);</li><li>or a family member has had asthma, nasal polyps, chronic sinusitis or chronic urticaria (hives);</li><li>have a history of stomach upset, ulcers, liver or kidney diseases;</li><li>have blood or urine abnormalities;</li><li>have high blood pressure;</li><li>have diabetes;</li><li>are on any special diet, such as a low&ndash;sodium or low&ndash;sugar diet;</li><li>are pregnant or intend to become pregnant while taking this medication;</li><li>are breast feeding or intend to breast feed while taking this medication. Naproxen passes into the milk of nursing women;</li><li>are taking any other medication (either prescription or non-prescription) such as other NSAIDs, high blood pressure medication, blood thinners, corticosteroids, methotrexate, cyclosporin, lithium, phenytoin;</li><li>have any other medical problem(s) such as alcohol abuse, bleeding problems, etc.</li></ul><p>&nbsp;</p><p><strong><u>b-</u></strong><strong><u> </u></strong><strong><u>Take</u></strong><strong><u> </u></strong><strong><u>special care</u></strong></p><p>Stomach upset is one of the common problems with NSAIDs. To lessen stomach upset, take this medicine immediately after a meal or with food or milk. Also, you should remain standing or sitting upright (i.e. do not lie down) for about 15-30 minutes after taking the medicine. This helps to prevent irritation that may lead to trouble swallowing. If stomach upset (indigestion, nausea, vomiting, stomach pain or diarrhea) occurs and continues, contact your doctor.</p><p>Do not take ASA (acetylsalicylic acid), ASA&ndash;containing compounds or other drugs used to relieve symptoms of arthritis while taking NAPROTEX unless directed to do so by your physician.</p><p>If you are prescribed this medication for use over a long period of time, your doctor will check your health during regular visits to assess your progress and to ensure that this medicine is not causing unwanted effects.</p><p>Your condition, as your doctor may have explained to you, has its ups and downs. The amount of pain, stiffness, and inflammation in your joints may vary from week to week. As time goes by, your doctor may decide that it is advisable to make adjustments in the dosage of NAPROTEX you are taking. He or she may suggest that you increase or decrease your medication according to how severe your symptoms are or how active you are.</p><p>Follow instructions; your doctor understands how to set the upper and lower dosage limits so that you get the greatest benefit from NAPROTEX.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- <u>How to take NAPROTEX</u></strong></p><p>NAPROTEX is available in easy to swallow tablets. You should take NAPROTEX only as directed by your doctor. Do not take more of it, do not take it more often and do not take it for a longer period of time than your doctor ordered. Taking too much of any of these medicines may increase the chance of unwanted effects, especially if you are an elderly patient. Be sure to take NAPROTEX regularly as prescribed. In some types of arthritis, up to two weeks may pass before you feel the full effects of this medicine. During treatment, your doctor may decide to adjust the dosage according to your response to the medication.</p><p>Usually NAPROTEX tablets are prescribed to be taken twice a day; it doesn&rsquo;t need to be taken more often than that. You don&rsquo;t have to carry your medication with you everywhere - just take one dose in the morning and one dose in the evening. For the most relief, take your NAPROTEX at the same time each day. It&rsquo;s important to keep taking NAPROTEX even after you start to feel better. This helps to keep your pain, tenderness, and stiffness under control. You should take NAPROTEX with food or milk.</p><p>Your doctor may give you different instructions better suited to your specific needs. If you need more information about how to take NAPROTEX properly, double&ndash;check with your doctor or pharmacist. NAPROTEX is completely absorbed into your system usually within two to four hours. Some people are able to feel improvement in their symptoms right away; for others, improvement may take up to two weeks. By the end of two weeks, if NAPROTEX does not seem to be helping you, tell your doctor. You may need a different dosage, or your doctor may want to prescribe another treatment program for you.</p><p>&nbsp;</p><p><strong><u>b- While taking NAPROTEX</u></strong></p><ul><li>tell any other doctor, dentist or pharmacist that you consult or see that you are taking this medication;</li><li>some NSAIDs may cause drowsiness or fatigue in some people taking them. Be cautious about driving or participating in activities that require alertness if you are drowsy, dizzy or lightheaded after taking this medication;</li><li>check with your doctor if you are not getting any relief of your arthritis or if any problems develop;</li><li>report any untoward reactions to your doctor. This is very important as it will aid in the early detection and prevention of potential complications.</li><li>stomach problems may be more likely to occur if you drink alcoholic beverages. Therefore, do not drink alcoholic beverages while taking this medication;</li><li>check with your doctor immediately if you experience unexpected weakness while taking this medication, or if you vomit any blood or have dark or bloody stools;</li><li>some people may become more sensitive to sunlight than they are normally. Exposure to sunlight or sunlamps, even for brief periods of time, may cause sunburn, blisters on the skin, skin rash, redness, itching or discoloration; or vision changes. If you have a reaction from the sun, check with your doctor;</li><li>check with your doctor immediately if chills, fever, muscle aches or pains, or other flu&ndash;like symptoms occur, especially if they occur shortly before, or together with, a skin rash. Very rarely, these effects may be the first signs of a serious reaction to this medication;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Along with its beneficial effects, naproxen, like other NSAID drugs, may cause some undesirable reactions especially when used for a long time or in large doses.</p><p>&nbsp;</p><p>Elderly, frail or debilitated patients often seem to experience more frequent or more severe side effects. Although not all of these side effects are common, when they do occur they may require medical attention. <strong>CHECK WITH YOUR DOCTOR IMMEDIATELY IF ANY OF THE FOLLOWING ARE NOTED:</strong></p><ul><li>bloody or black tarry stools;</li><li>shortness of breath, wheezing, any trouble in breathing, or tightness in the chest;</li><li>skin rash, hives or swelling, itching;</li><li>vomiting or persistent indigestion, nausea, stomach pain or diarrhea;</li><li>yellow discoloration of the skin or eyes;</li><li>any change in the amount of or colour of your urine (dark red or brown);</li><li>any pain or difficulty experienced while urinating;</li><li>swelling of the feet or lower legs;</li><li>malaise, fatigue, loss of appetite;</li><li>blurred vision or any visual disturbance;</li><li>mental confusion, depression, dizziness, lightheadedness;</li><li>hearing problems.</li></ul><p>Other side effects not listed above may also occur in some patients. If you notice any other effects, check with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Store at below 25&deg;C.</li><li>Do not keep outdated medicine or medicine no longer needed.</li><li>Keep out of the reach of children.</li><li>This medication has been prescribed for your medical problem. Do not give it to anyone else.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Naproxen.</p><p>The other ingredients are methylcellulose, croscarmellose sodium, magnesium stearate, and colloidal silicon dioxide. The 250 and the 500 mg tablets also contain D&amp;C yellow #10 and FD&amp;C yellow #6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NAPROTEX 250 mg tablets:
Each yellow, oval, biconvex tablet engraved “APO-250” on one side contains 250 mg naproxen. It is available in blisters of 20 Tablet.

NAPROTEX 500 mg tablets:
Each yellow, capsule-shaped, biconvex tablet, scored and engraved “APO 500” on one side, contains 500 mg naproxen. It is available in blisters of 10 Tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised on 01/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما تأثير الدواء نابروتكس</strong></p><p>دواء نابروتكس (نابروكسين) الموصوف لك بواسطة طبيبك، هو أحد الأدوية بالمجموعة الكبيرة لمضادات الالتهاب اللاستيرويدية (المسماة كذلك NSAIDS). يُستخدم لعلاج أعراض أنواع معينة من التهاب المفاصل، ويساعد في علاج ألم المفاصل، والتورم، والتصلب، والحمى، وذلك بتقليل إنتاج مواد معينة (البروستاجلاندينات)، وبالمساعدة في كبح الالتهاب.<br />&nbsp;</p><p><strong>دواعي استعمال هذا الدواء</strong></p><p>مضادات الالتهاب اللاستيرويدية لا تشفي من التهاب المفاصل، ولكنها تحفز كبح الالتهاب والتأثيرات الضارة بالأنسجة الناتجة عن الالتهاب، هذا الدواء لن يكون مفيداً إلا مع استمرار استخدامك له.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- لا يؤخذ نابروتكس في الحالات التالية:</strong></p><p>قبل استخدام هذا الدواء أبلغ طبيبك في الحالات التالية:</p><ul><li>إذا كنت أنت أو أحد أفراد أسرتك مصاباً بالحساسية، أو تعرضت مسبقاً لتفاعل مع استخدام نابروكسين أو أي من مضادات الالتهاب الأخرى (مثل حمض الأسيتيل ساليسيليك (الأسبرين)، ديكلوفيناك، دايفلونيزال، فينوبروفين، فلوربايبروفين، إيبوبروفين، إيندوميثاسين، كيتوبروفين، حمض الميفيناميك، نابروكسين صوديوم، بايروكزيكام، حمض التيابروفينيك، تولميتين، نابيوميتون، تينوكزيكام)، يظهر هذا التفاعل في صورة التهاب متزايد بالجيوب الأنفية، شري جلدي، وبدء التعرض للربو أو زيادة سوء أعراضه، أو الإعورار المناعي (السقوط المفاجئ).</li><li>إذا كنت أنت أو أحد أفراد أسرتك مصاباً بالربو، الزوائد اللحمية الأنفية، الالتهاب المزمن بالجيوب الأنفية، أو الأرتيكاريا المزمنة (الشري الجلدي).</li><li>إذا سبق لك الإصابة بتهيج المعدة، القرحة، أمراض الكلى أو الكبد.</li><li>إذا كان لديك مشكلات بالدم أو البول.</li><li>إذا كنت مصاباً بارتفاع ضغط الدم.</li><li>إذا كنت مصاباً بالسكريّ.</li><li>إذا كنت خاضعاً لأي نظام غذائي خاص، كالنظام الغذائي منخفض الصوديوم أو النظام الغذائي منخفض السكر.</li><li>إذا كنتِ حاملاً، أو تنوين الحمل أثناء فترة استخدامك هذا الدواء.</li><li>إذا كنتِ مرضعة، أو تنوين الرضاعة أثناء فترة استخدامك هذا الدواء، يمر نابروكسين إلى لبن الثدي للمرضعات.</li><li>إذا كنت تستخدم أية أدوية (سواء بوصفة طبية أو بدونها) مثل مضادات الالتهاب اللاستيرويدية الأخرى، أدوية ارتفاع ضغط الدم، مخففات الدم، الستيرويدات القشرية، ميثوتريكسيت، سايكلوسبورين، ليثيوم، فينيتوين.</li><li>إذا كانت لديك أي مشكلة طبية مثل: إدمان الكحوليات، أو مشكلات النزف، إلخ.</li></ul><p>&nbsp;</p><p><strong>ب- كن على حذر بصفة خاصة في الحالات التالية</strong></p><p>تهيج المعدة هو أحد الأعراض الشائعة مع استخدام مضادات الالتهاب اللاستيرويدية، ولتقليل هذا التهيج، قم باستخدام الدواء فور تناولك لوجباتك مباشرة، أو مع الطعام أو الحليب، عليك كذلك أن تظل واقفاً أو جالساً بشكل منتصب (أي لا تنحني) لمدة 15-30 دقيقة بعد استخدام هذا الدواء، يساعد ذلك على منع الاستثارة التي قد تؤدي إلى مشاكل بالبلع، وفي حالة تهيج المعدة (عسر الهضم، الغثيان، القيء، ألم المعدة، أو الإسهال)، أبلغ طبيبك.</p><p>لا تستخدم حمض الأسيتيل ساليسيليك، والمركبات التي تحتوي عليه، والأدوية الأخرى المستخدمة لعلاج أعراض التهاب المفاصل مع استخدام نابروتكس، إلا إذا كان ذلك بطلب من طبيبك.</p><p>إذا تم وصف هذا الدواء لك لاستخدامه لفترة طويلة من الوقت، فسيطمئن طبيبك على صحتك من خلال زيارات منتظمة، وذلك لتقييم تحسنك، وضمان عدم تسبب هذا الدواء في أي أعراض غير مرغوبة.</p><p>حالتك متقلبة كما سيشرح لك طبيبك، وتتفاوت درجة الألم أو التصلب أو الالتهاب بمفاصلك من أسبوع إلى آخر، ومع الوقت قد يقرر طبيبك أنه من المستحسن ضبط جرعة نابروتكس التي تستخدمها، وقد يقترح/تقترح زيادة أو نقص جرعة دوائك &nbsp;بحسب شدة الأعراض التي تعاني منها، أو مدى نشاطك.</p><p>اتبّع التعليمات، طبيبك يفهم كيفية تحديد الحد الأدنى والأقصى للجرعة بحيث تحقق أكبر استفادة ممكنة من نابروتكس.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ&zwnj;. كيفية تناول الدواء نابروتكس</strong></p><p>نابروتكس متاح في أقراص سهلة البلع، يجب عليك استخدام نابروتكس فقط بحسب إرشادات الطبيب، لا تستخدم المزيد منه، ولا تستخدمه بأكثر من المعتاد، ولا تستخدمه لمدة أطول ممّا طلب طبيبك، الاستخدام المُفرط لهذه الأدوية قد يزيد من فرصة التعرض لمضاعفات غير مرغوبة، خاصة إذا كنت من المرضى المسنين، &nbsp;تأكد من &nbsp;استخدام &nbsp;نابروتكس &nbsp;بشكل &nbsp;منتظم &nbsp;كما &nbsp;هو&nbsp;موصوف لك، وفي بعض أنواع التهاب المفاصل قد يمر أسبوعان قبل الشعور بالتأثيرات الكاملة لهذا الدواء، وخلال فترة العلاج قد يقرر طبيبك ضبط الجرعة بحسب الاستجابة للدواء.</p><p>عادة ما يتم وصف أقراص نابروتكس للاستخدام مرتين يومياً، ولا حاجة لاستخدامها بما يزيد عن ذلك، ولا حاجة لحمل دوائك معك في كل مكان، فقط عليك أخذ جرعة صباحاً وأخرى مساءً، وللراحة القصوى استخدام نابروتكس في نفس الوقت يومياً، ومن المهم المداومة على استخدام نابروتكس حتى بعد بداية شعورك بالتحسن، سيساعد ذلك على كبح الألم والألم مع اللمس وكذلك التصلب، يجب عليك استخدام نابروتكس مع الطعام أو الحليب.</p><p>قد يعطيك طبيبك تعليمات مختلفة لتكون أكثر ملاءمة لاحتياجاتك المحددة، إذا كنت في حاجة لمزيد من المعلومات بخصوص كيفية استخدام نابروتكس بشكل ملائم، تأكد مرة أخرى من طبيبك أو الصيدلي، يتم امتصاص نابروتكس بشكل كامل إلى نظامك الجسماني عادة خلال 2-4 ساعات، بعض الأشخاص يمكنهم الشعور بتحسن أعراضهم فوراً، أما الآخرون فقد يستغرقون مدة تصل إلى أسبوعين، إذا لم يبدُ نابروتكس مفيداً مع نهاية الأسبوعين، أبلغ طبيبك، قد تحتاج لجرعة مختلفة، أو قد يريد طبيبك أن يصف لك برنامجاً علاجياً مختلفاً.</p><p><strong>ب- أثناء استخدام نابروتكس</strong></p><ul><li>أبلغ أي طبيب، أو طبيب أسنان، أو أي صيدلي تستشيره بخصوص استخدامك لهذا الدواء.</li><li>قد تسبب بعض مضادات الالتهاب اللاستيرويدية الدوخة أو الدوار في بعض الأشخاص من مستخدميها، فكن حذراً بخصوص القيادة أو المشاركة في أنشطة تتطلب الانتباه وإذا شعرت بالدوخة أو التشوش أو خفّة الرأس بعد استخدام هذا الدواء.</li><li>راجع طبيبك إذا لم تشعر بتحسن التهاب المفاصل، أو في حالة حدوث أية مشكلة.</li><li>أبلغ طبيبك بأي تفاعلات غير مرغوبة، وهذا أمر بالغ الأهمية، حيث إنه قد يساعد في الاكتشاف المبكر لأي مضاعفات ومنعها.</li><li>مشكلات المعدة قد تكون هي الأكثر احتمالاً للحدوث مع تعاطي المشروبات الكحولية، ولذلك لا تشرب الكحوليات أثناء استخدام هذا الدواء.</li><li>راجع طبيبك فوراً إذا شعرت بضعف غير متوقع أثناء استخدام هذا الدواء، أو إذا عانيت من القيء الدموي أو البراز الدموي.</li><li>قد يصبح بعض الأشخاص أكثر حساسية لضوء الشمس بأكثر من الطبيعي، وقد يسبب التعرض لضوء الشمس أو المصابيح الشمسية حتى لفترات بسيطة من الوقت الإصابة بحروق شمسية، بثور بالجلد، طفح جلدي، إحمرار، هرش، تغير بلون الجلد، أو تغيرات بالرؤية، وفي حالة شكواك من تفاعل مع التعرض للشمس راجع طبيبك.</li><li>راجع طبيبك فوراً إذا شكوت من رعشة، حمى، ألم عضلي، أو أي ألم، أو أعراض شبيهة بالإنفلونزا، وخاصة إذا حدثت قبل الإصابة بالطفح الجلدي مباشرة أو صاحبته، وفي حالات نادرة جداً قد تكون هذه الأعراض هي العلامات الأولى على تفاعل خطير مع هذا الدواء.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مع تأثيراته المفيدة، فقد يسبب نابروكسين _كغيره من مضادات الالتهاب اللاستيرويدية_ بعض التفاعلات غير المرغوبة، خاصة عند استخدامه لفترات طويلة أو بجرعات كبيرة.</p><p>المرضى من المسنين أو المصابين بالضعف أو الإنهاك غالباً ما يكونون أكثر عُرضة للإصابة بأعراض جانبية متكررة أو عنيفة.</p><p>بالرغم من عدم شيوع كل هذه الأعراض الجانبية، فقد تتطلب الرعاية الطبية عند حدوثها.</p><p><strong>راجع طبيبك فوراً عند ملاحظة أي من الأعراض التالية:</strong></p><ul><li dir="rtl">تلون البراز بالدم أو اللون الأسود القطراني</li><li dir="rtl">قِصَر النفس، الصفير التنفسي، أو أي مشكلة بالتنفس، أو ضيق الصدر.</li><li dir="rtl">الطفح الجلدي، الشري الجلدي، التورم، الهرش.</li><li dir="rtl">اصفرار الجلد أو العينين.</li><li>أي تغير في كمية البول أو لونه (أحمر داكن أو بنيّ)</li><li>أي ألم أو صعوبة مع التبول.</li><li>تورم القدمين أو الجزء السفليّ من الساقين.</li><li>الإحساس بالتوعك، التعب، فقد الشهية.</li><li>تشوش الرؤية أو أي اضطرابات بالرؤية.</li><li>التشوش الذهني، الاكتئاب، الدوخة، خفة الرأس.</li><li>مشكلات السمع.</li></ul><p>بعض الأعراض الجانبية الأخرى غير المذكورة أعلاه قد تحدث في بعض</p><p>&nbsp;المرضى، عند ملاحظتك لأي أعراض أخرى، أبلغ طبيبك.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="rtl">&nbsp;يُخزَن في درجة حرارة أقل من 25 درجة مئوية.</li><li>لا تحتفظ بالأدوية منتهية الصلاحية، أو الأدوية التي لم تعد في حاجة إليها.</li><li>يُحفظ بعيداً عن متناول الأطفال.</li><li>تم وصف هذا الدواء لمشكلتك الطبية، فلا تقدمه لآخرين.</li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>المادة الفعالة هي نابروكسين</li><li>المواد الاخرى هي بلورات السليولوز الدقيقة، ميثيل سيليولوز، كروسماللوز صوديوم، ماغنسيوم ستيريت، وثاني أكسيد السليكون الغروي، كما تحتوي &nbsp;الأقراص بجرعة 250 ملجم و 500 ملجم على الصبغة الصفراء رقم 10، وصبغة شروق الشمس الصفراء رقم 6 كذلك.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>أقراص نابروتكس 250 ملجم:</strong></p><p>كل قرص أصفر بيضاوي ثنائي التقعر محفور عليه &quot;APO-250&quot; على أحد الجانبين، يحتوي على 250 ملجم من نابروكسين. ويوجد في علبة شرائط وتحتوي 20 اقراص.</p><p><strong>أقراص نابروتكس 500 ملجم:</strong></p><p>كل قرص أصفر كبسولي الشكل ثنائي التقعر، مخطط ومحفور عليه &quot;APO 500&quot; على أحد الجانبين، يحتوي على 500 ملجم من نابروكسين. ويوجد في علبة شرائط وتحتوي 10 اقراص.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>أبوتكس إنك، تورنتو، أونتاريو، ام 9 ال 1تي9 كندا.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة في: 01/2014

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NAPROTEX, Naproxen Tablets 250 and 500 mg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NAPROXEN is available as:
APO-NAPROXEN 125 mg tablets: Each pale green, oval, biconvex tablet engraved “APO-125” on one side, contains 125 mg naproxen. Available in bottles of 100 and 500 tablets and in unit dose packages of 100 (10x10).
NAPROTEX 250 mg tablets: Each yellow, oval, biconvex tablet engraved “APO-250” on one side contains 250 mg naproxen. Available in bottles of 100 and 1000 tablets and unit dose packages of 100 (10x10).
APO-NAPROXEN 375 mg tablets: Each peach-coloured, capsule-shaped, biconvex  tablet, scored and engraved “APO 375” on one side, contains 375 mg naproxen. Available in bottles of 100 and 500 tablets and unit dose packages of 100 (10x10).
NAPROTEX 500 mg tablets: Each yellow, capsule-shaped, biconvex tablet, scored and engraved “APO 500” on one side, contains 500 mg naproxen. Available in bottles of 100 and 500 tablets and unit dose packages of 100 (10x10).
Sustained-Release Tablets:
APO-NAPROXEN SR 750 mg tablets: Each peach, capsule-shaped, biconvex tablet, engraved “APO-750” on one side, contains 750 mg of naproxen. Available in bottles of 100 and 500 and unit dose packages of 100 (10x10).
Enteric-Coated Tablets:
APO-NAPROXEN EC 250 mg tablets: Each white, round, biconvex, enteric-coated tablet, engraved “APO” on one side, and “250” on the other side, contains 250 mg of naproxen. Available in bottles of 100 and 500 and unit dose packages of 60 (6 x 10).
APO-NAPROXEN EC 375 mg tablets: Each white, capsule-shaped, biconvex, enteric-coated tablet, engraved “APO” on one side, and “375” on the other side, contains 375 mg of naproxen. Available in bottles of 100 and 500 and unit dose packages of 60 (6 x 10).
APO-NAPROXEN EC 500 mg tablets: Each white, capsule-shaped, biconvex, enteric-coated tablet, engraved “APO” on one side, and “500” on the other side contains 500 mg of naproxen. Available in bottles of 100 and 500 and unit dose packages of 30 (3 x 10).
Naproxen Tablets contain the following non-medicinal ingredients: methylcellulose, croscarmellose sodium, magnesium stearate, and colloidal silicon dioxide. The 250 and the 500 mg tablets also contain D&C yellow #10 and FD&C yellow #6; the 375 mg tablets contain only the latter; the 125 mg tablets contain the former and FD&C blue #2.
 
APO-NAPROXEN SR tablets contain the following non-medicinal ingredients hydroxypropyl methylcellulose, FD&C yellow #6, D&C yellow #10, and magnesium stearate.
APO-NAPROXEN EC tablets contain the following non-medicinal ingredients methylcellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hydroxyethyl cellulose, polyethylene glycol, titanium dioxide, triethyl citrate, talc and methacrylic acid copolymer.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NAPROTEX Tablets, 250 and 500 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Naproxen is indicated for:</strong></p><ul><li>The treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.</li><li>The relief of minor aches and pains in muscles, bones and joints, mild to moderate pain accompanied by inflammation in musculoskeletal injuries (sprains and strains) and primary dysmenorrhea.</li></ul><p>Modified release formulations of Naproxen (i.e., APO-NAPROXEN EC and APO-NAPROXEN SR) are not recommended for initial treatment of acute pain because the absorption of Naproxen is delayed.</p><p>&nbsp;</p><p><strong>For patients with an increased risk of developing cardiovascular and/or gastrointestinal adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first. (See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS).</strong></p><p><strong>Use of Naproxen should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal adverse events. (See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS)</strong></p><p>Naproxen, as a NSAID, does NOT treat clinical disease or prevent its progression.</p><p>Naproxen, as a NSAID, only relieves symptoms and decreases inflammation for as long as the patient continues to take it.</p><p><strong>Geriatrics (&gt; 65 years of age):</strong></p><p>Evidence from clinical studies and postmarket experience suggests that use in the geriatric population is associated with differences in safety (see WARNINGS AND PRECAUTIONS).</p><p><strong>Pediatrics (&lt; 2 years of age):</strong></p><p>Naproxen should not be used in children under 2 years of age. The safety and efficacy in infants younger than 2 years of age has not been established.</p><p>APO-NAPROXEN EC and APO-NAPROXEN SR have not been studied in subjects under the age of 18.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adult</strong></p><p><em>Osteoarthritis</em><em> / Rheumatoid Arthritis / Ankylosing Spondylitis</em></p><p><strong>Oral: </strong>The usual total daily dosage for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis is 500 mg a day in divided doses. &nbsp;It may be increased gradually to 750 or 1000 mg, or decreased, depending on the response of the patient.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="3"><p style="text-align:center">Recommended Daily Dosing</p></td></tr><tr><td style="vertical-align:top"><p><strong>NAPROXEN</strong></p></td><td style="vertical-align:top"><p>125 mg</p><p>or 250 mg</p><p>or 375 mg</p><p>or 500 mg</p></td><td style="vertical-align:top"><p>twice daily</p><p>twice daily</p><p>twice daily</p><p>twice daily</p></td></tr><tr><td style="vertical-align:top"><p><strong>APO-NAPROXEN EC</strong></p></td><td style="vertical-align:top"><p>250 mg</p><p>or 375 mg</p><p>or 500 mg</p></td><td style="vertical-align:top"><p>twice daily</p><p>twice daily</p><p>twice daily</p></td></tr><tr><td style="vertical-align:top"><p><strong>APO-NAPROXEN SR</strong></p></td><td style="vertical-align:top"><p>750 mg</p></td><td style="vertical-align:top"><p>once daily</p></td></tr></tbody></table><p>&nbsp;</p><p>Studies have not shown any clinically significant benefit in using doses higher than 1000 mg/day. &nbsp;In patients who tolerate lower doses of naproxen well and who exhibit only a partial response to 100 mg/day, the dose may be increased to 1500 mg/day for <u>limited periods</u>.</p><p>Experience with 1500 mg/day naproxen is limited to using the standard tablets.&nbsp; Naproxen (naproxen) tablets should be swallowed with food or milk.</p><p>When treating such patients with naproxen 1500 mg/day, the physician should observe sufficient increased clinical benefit to offset the potential increased risk (see Undesirable effects).</p><p>In addition, patients on 1500 mg/day need to be followed closely for the development of any adverse events.</p><p>During long&ndash;term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient.&nbsp; A lower dose may suffice for long&ndash;term administration.</p><p>Patients with rheumatoid arthritis or osteoarthritis maintained on a dose of 750 mg/day in divided doses can be switched to a once daily dose of APO-NAPROXEN SR (naproxen sustained- release) 750 mg.&nbsp; The single daily dose of APO-NAPROXEN SR should not be exceeded and can be administered in the morning or evening. APO-NAPROXEN SR tablets should be swallowed whole.</p><p>Naproxen sustained-release tablets and naproxen enteric-coated tablets have not been studied in subjects under the age of 18.</p><p>&nbsp;</p><p><em>Analgesia</em><em> / Musculoskeletal Injuries</em></p><p><strong>Oral: </strong>The recommended dose is 750 mg/day divided into either two or three doses/day. This may be increased to 1000 mg/day if needed. The lowest effective dose should be used.</p><p>Modified release formulations of naproxen (i.e. enteric-coated and sustained-release) are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed.</p><p>&nbsp;</p><p><em>Dysmenorrhea</em></p><p><strong>Oral: </strong>The recommended starting dose is two 250 mg tablets, followed by one 250 mg tablet every 6 &ndash; 8 hours, as required. The total daily dose should not exceed 5 tablets (1250 mg). Alternatively, one 500 mg tablet given twice daily may be used.</p><p>Modified release formulations of naproxen (i.e. enteric-coated and sustained-release) are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed.</p><p>&nbsp;</p><p><strong><u>Missed Dose</u></strong></p><p>The missed dose should be taken as soon as remembered, and then the regular dosing schedule should be continued. Two doses of Naproxen should not be taken at the same time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Naproxen is contraindicated in:

• the peri-operative setting of coronary artery bypass graft surgery (CABG). Although Naproxen has NOT been studied in this patient population, a selective COX-2 inhibitor NSAID studied in such a setting has led to an increased incidence of cardiovascular/thromboembolic events, deep surgical infections and sternal wound complications.
• the third trimester of pregnancy, because of risk of premature closure of the ductus arteriosus and prolonged parturition women who are breastfeeding, because of the potential for serious adverse reactions in nursing infants
• severe uncontrolled heart failure
• known hypersensitivity to naproxen or to any of the components/excipients
• history of asthma, urticaria, or allergic-type reactions after taking ASA or other NSAIDs (i.e. complete or partial syndrome of ASA-intolerance rhinosinusitis, urticaria/angioedema, nasal polyps, asthma). Fatal anaphylactoid reactions have occurred in such individuals. Individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse reaction. The potential for cross-reactivity between different NSAIDs must be kept in mind (see WARNINGS AND PRECAUTIONS: Hypersensitivity Reactions, Anaphylactoid Reactions).
• active gastric / duodenal / peptic ulcer, active GI bleeding.
• cerebrovascular bleeding or other bleeding disorders
• inflammatory bowel disease
• severe liver impairment or active liver disease
• severe renal impairment (creatinine clearance <30 mL/min or 0.5 mL/sec) or deteriorating renal disease (individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs and must be monitored) (see WARNINGS AND PRECAUTIONS: Renal)
• known hyperkalemia (see WARNINGS AND PRECAUTIONS: Renal, Fluid and Electrolyte Balance)
• children less than 2 years of age.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>GENERAL</u></strong></p><p>Frail or debilitated patients may tolerate side effects less well and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse event, the lowest effective dose should be used for the shortest possible duration. As with other NSAIDs, caution should be used in the treatment of elderly patients who are more likely to be suffering from impaired renal, hepatic or cardiac function. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</p><p>Naproxen is NOT recommended for use with other NSAIDs, with the exception of low-dose ASA for cardiovascular prophylaxis, because of the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions. (See DRUG INTERACTIONS: Drug-Drug Interactions, Acetylsalicylic acid (ASA) or other NSAIDs)</p><p>Naproxen should not be used concomitantly with the related drug APO-NAPRO-NA (naproxen sodium) since they both circulate in plasma as the naproxen anion.</p><p><u>Carcinogenesis and Mutagenesis</u></p><p>There is no evidence from animal data that Naproxen is carcinogenic or mutagenic (see Part II, TOXICOLOGY, for animal studies).</p><p><u>Cardiovascular and Cerebrovascular Events</u></p><p><strong>Naproxen</strong><strong> </strong><strong>is a non-steroidal anti-inflammatory drug (NSAID). Use of some NSAIDs is associated with an increased incidence of cardiovascular adverse events (such as myocardial infarction, stroke or thrombotic events) which can be fatal. The risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.</strong></p><p><strong>Caution</strong><strong> should be exercised in prescribing&nbsp; Naproxen to patients with risk factors for cardiovascular disease, cerebrovascular disease or renal disease, such as any of the following (NOT an exhaustive list):</strong></p><ul><li><strong>Hypertension</strong></li><li><strong>Dyslipidemia</strong><strong> / Hyperlipidemia</strong></li><li><strong>Diabetes</strong><strong> Mellitus</strong></li><li><strong>Congestive </strong><strong>Heart Failure (NYHA I)</strong></li><li><strong>Coronary</strong><strong> Artery Disease (Atherosclerosis)</strong></li><li><strong>Peripheral</strong><strong> Arterial Disease</strong></li><li><strong>Smoking</strong></li><li><strong>Creatinine Clearance </strong><strong>&lt; 60 mL/min or 1 mL/sec</strong></li></ul><p>&nbsp;</p><p>Use of NSAIDs, such as Naproxen, can lead to new hypertension or can worsen pre-existing hypertension, either of which may increase the risk of cardiovascular events as described above. Thus blood pressure should be monitored regularly. Consideration should be given to discontinuing Naproxen should hypertension either develop or worsen with its use.</p><p>Use of NSAIDs, such as Naproxen, can induce fluid retention and edema, and may exacerbate congestive heart failure, through a renally-mediated mechanism. (See WARNINGS AND PRECAUTIONS: Renal, Fluid and Electrolyte Balance).</p><p>For patients with a high risk of developing an adverse CV event, other management strategies that do NOT include the use of NSAIDs should be considered first. <strong>To minimize the potential risk for an adverse CV event, the lowest effective dose should be used for the shortest possible duration.</strong></p><p>&nbsp;</p><p><u>Endocrine and Metabolism</u></p><p><em>Corticosteroids: </em>Naproxen is NOT a substitute for corticosteroids. It does NOT treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. (see DRUG INTERACTIONS: Drug-Drug Interactions, Glucocorticoids)</p><p>&nbsp;</p><p><u>Gastrointestinal</u></p><p>Serious GI toxicity, such as peptic ulceration, inflammation gastrointestinal bleeding, <u>sometimes</u> <u>severe and occasionally fatal </u>can occur at any time, with or without warning symptoms in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs) including Naproxen (naproxen).</p><p>Minor upper GI problems, such as dyspepsia, are common, usually developing early in therapy. Health care providers should remain alert for ulceration and bleeding in patients treated with Naproxen, even in the absence of previous GI tract symptoms. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. (see WARNINGS AND PRECAUTIONS: Special Populations, Geriatrics)</p><p>Physicians should inform patients about the signs and/or symptoms of serious GI toxicity and instruct them to contact a physician immediately if they experience any such symptoms. The utility of periodic laboratory monitoring has NOT been demonstrated, nor has it been adequately assessed. Most patients who develop a serious upper GI adverse event on NSAID therapy have no symptoms. Upper GI ulcers, gross bleeding or perforation, caused by NSAIDs, appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. These trends continue, thus increasing the likelihood of developing a serious GI event at some time during the course of therapy. Even short-term therapy has its risks.</p><p>Caution should be taken if prescribing Naproxen to patients with a prior history of peptic / duodenal ulcer disease or gastrointestinal bleeding as these individuals have a greater than 10- fold higher risk for developing a GI bleed when taking a NSAID than patients with neither of these risk factors. Other risk factors for GI ulceration and bleeding include the following: <em>Helicobacter pylori </em>infection, increased age, prolonged use of NSAID therapy, excess alcohol intake, smoking, poor general health status or concomitant therapy with any of the following:</p><ul><li>Anti-coagulants (e.g. warfarin)</li><li>Anti-platelet agents (e.g. ASA, clopidogrel)</li><li>Oral corticosteroids (e.g. prednisone)</li><li>Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g. citalopram, fluoxetine, paroxetine, sertraline)</li></ul><p><u>Genitourinary</u></p><p>Some NSAIDs are associated with persistent urinary symptoms (bladder pain, dysuria, urinary frequency), hematuria or cystitis. The onset of these symptoms may occur at any time after the initiation of therapy with a NSAID. Should urinary symptoms occur, in the absence of an alternate explanation, treatment with Naproxen should be stopped to ascertain if symptoms disappear. This should be done before urological investigations or treatments are carried out.</p><p>&nbsp;</p><p><u>Hematologic</u></p><p>NSAIDs inhibiting prostaglandin biosynthesis interfere with platelet function to varying degrees; patients who may be adversely affected by such an action, such as those on anti-coagulants or suffering from haemophilia or platelet disorders should be carefully observed when Naproxen is administered.</p><p><em>Anti-coagulants: </em>Numerous studies have shown that the concomitant use of NSAIDs and anticoagulants increases the risk of bleeding. Concurrent therapy of Naproxen with warfarin requires close monitoring of the international normalized ratio (INR).</p><p>Even with therapeutic INR monitoring, increased bleeding may occur.</p><p><em>Anti-platelet Effects</em>: NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike acetylsalicylic acid (ASA), their effect on platelet function is quantitatively less, or of shorter duration, and is reversible.</p><p>Naproxen and other NSAIDs have no proven efficacy as anti-platelet agents and should NOT be used as a substitute for ASA or other anti-platelet agents for prophylaxis of cardiovascular thromboembolic diseases. Anti-platelet therapies (e.g. ASA) should NOT be discontinued. There is some evidence that use of NSAIDs with ASA can markedly attenuate the cardioprotective effects of ASA. (see DRUG INTERACTIONS: Drug-Drug Interactions, Acetylsalicylic Acid or other NSAIDs)</p><p>Concomitant administration of Naproxen with low dose ASA increases the risk of GI ulceration and associated complications.</p><p><em>Blood dyscrasias</em>: Blood dyscrasias (such as neutropenia, leukopenia, thrombocytopenia, aplastic anemia and agranulocytosis) associated with the use of NSAIDs are rare, but could occur with severe consequences.</p><p>Anemia is sometimes seen in patients receiving NSAIDs, including Naproxen. This may be due to fluid retention, GI blood loss, or an incompletely described effect upon erythropoiesis.</p><p>Patients on long-term treatment with NSAIDs, including Naproxen, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia or blood loss.</p><p>&nbsp;</p><p><u>Hepatic/Biliary/Pancreatic</u></p><p>As with other NSAIDs, borderline elevations of one or more liver enzyme tests (AST, ALT, alkaline phosphatase) may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy.</p><p>Chronic alcoholic liver disease and probably also other forms of cirrhosis reduce the total plasma concentration of naproxen, but the plasma concentration of unbound naproxen is increased. The implication of this finding for naproxen dosing is unknown, but caution is advised when high doses are required. It is prudent to use the lowest effective dose.</p><p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with this drug. Severe hepatic reactions including jaundice and cases of fatal hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes, have been reported with NSAIDs.</p><p>Although such reactions are rare, if abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop (e.g. jaundice), or if systemic manifestations occur (e.g. eosinophilia, associated with rash, etc.), this drug should be discontinued.</p><p>If there is a need to prescribe this drug in the presence of impaired liver function, it must be done under strict observation.</p><p>&nbsp;</p><p><strong>Hypersensitivity Reactions:</strong></p><p><em>Anaphylactoid Reactions</em>: As with NSAIDs in general, anaphylactoid reactions have occurred in patients without known prior exposure to Naproxen. In post-marketing experience, rare cases of anaphylactic/ anaphylactoid reactions and angioedema have been reported in patients receiving Naproxen. Naproxen should NOT be given to patients with the ASA-triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking ASA or other NSAIDs (see CONTRAINDICATIONS).</p><p><em>ASA-Intolerance</em>: Naproxen should NOT be given to patients with complete or partial syndrome of ASA-intolerance (rhinosinusitis, urticaria/angioedema, nasal polyps, asthma) in whom asthma, anaphylaxis, urticaria/angioedema, rhinitis or other allergic manifestations are precipitated by ASA or other NSAIDs. Fatal anaphylactoid reactions have occurred in such individuals. As well, individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse reaction (see CONTRAINDICATIONS).</p><p><em>Cross-sensitivity: </em>Patients sensitive to one NSAID may be sensitive to any of the other NSAIDs as well.</p><p><em>Serious</em><em> skin reactions: </em>(See WARNINGS AND PRECAUTIONS: Skin)</p><p>&nbsp;</p><p><u>Immune</u></p><p>(See WARNINGS AND PRECAUTIONS: Infection, Aseptic Meningitis)</p><p>&nbsp;</p><p><u>Infection</u></p><p>Naproxen, in common with other NSAIDs, may mask signs and symptoms of an underlying infectious disease.</p><p><em>Aseptic Meningitis: </em>Rarely, with some NSAIDs, the symptoms of aseptic meningitis (stiff neck, severe headaches, nausea and vomiting, fever or clouding of consciousness) have been observed. Patients with autoimmune disorders (systemic lupus erythematosus, mixed connective tissue diseases, etc.) seem to be pre-disposed. Therefore, in such patients, the health care provider must be vigilant to the development of this complication.</p><p>&nbsp;</p><p><u>Neurologic</u></p><p>Some patients may experience drowsiness, dizziness, blurred vision, vertigo, tinnitus, hearing loss, insomnia or depression with the use of NSAIDs, such as Naproxen. If patients experience such adverse reaction(s), they should exercise caution in carrying out activities that require alertness.</p><p>&nbsp;</p><p><u>Ophthalmologic</u></p><p>Blurred and/or diminished vision has been reported with the use of NSAIDs. If such symptoms develop, Naproxen should be discontinued and an ophthalmologic examination performed.</p><p>Ophthalmologic examination should be carried out at periodic intervals in any patient receiving Naproxen for an extended period of time.</p><p>&nbsp;</p><p><u>Peri-Operative Considerations</u></p><p>(See CONTRAINDICATIONS: Coronary Artery Bypass Graft Surgery)</p><p>&nbsp;</p><p><u>Psychiatric</u></p><p>(See WARNINGS AND PRECAUTIONS: Neurologic)</p><p>&nbsp;</p><p><u>Renal</u></p><p>Long term administration of NSAIDs to animals has resulted in renal papillary necrosis and other abnormal renal pathology. In humans, there have been reports of acute interstitial nephritis, hematuria, low grade proteinuria and occasionally nephrotic syndrome.</p><p>Renal insufficiency due to NSAID use is seen in patients with pre-renal conditions leading to reduction in renal blood flow or blood volume. Under these circumstances, renal prostaglandins help maintain renal perfusion and glomerular filtration rate (GFR). In these patients, administration of a NSAID may cause a reduction in prostaglandin synthesis leading to impaired renal function. Patients at greatest risk of this reaction are those with pre-existing renal insufficiency (GFR &lt; 60 mL/min or 1 mL/s), dehydrated patients, patients on salt restricted diets, those with congestive heart failure, cirrhosis, liver dysfunction, taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, cyclosporin, diuretics, and those who are elderly. Serious or life-threatening renal failure has been reported in patients with normal or impaired renal function after short term therapy with NSAIDs. Even patients at risk who demonstrate the ability to tolerate a NSAID under stable conditions may decompensate during periods of added stress (e.g. dehydration due to gastroenteritis). Discontinuation of NSAIDs is usually followed by recovery to the pre-treatment state.</p><p>Caution should be used when initiating treatment with NSAIDs, such as Naproxen, in patients with considerable dehydration. Such patients should be rehydrated prior to initiation of therapy. Caution is also recommended in patients with pre-existing kidney disease.</p><p>&nbsp;</p><p><strong><em>Advanced</em></strong><strong><em> Renal Disease</em></strong><em>: </em>(See CONTRAINDICATIONS)</p><p><strong><em>Fluid and Electrolyte Balance</em></strong>: Use of NSAIDs, such as Naproxen, can promote sodium retention in a dose-dependent manner, which can lead to fluid retention and edema, and consequences of increased blood pressure and exacerbation of congestive heart failure. Thus, caution should be exercised in prescribing Naproxen in patients with a history of congestive heart failure, compromised cardiac function, hypertension, increased age or other conditions predisposing to fluid retention (see WARNINGS AND PRECAUTIONS: Cardiovascular). Use of NSAIDs, such as Naproxen, can increase the risk of hyperkalemia, especially in patients with diabetes mellitus, renal failure, increased age, or those receiving concomitant therapy with adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, cyclosporin, or some diuretics.</p><p>Electrolytes should be monitored periodically (see CONTRAINDICATIONS).</p><p>&nbsp;</p><p><u>Respiratory</u></p><p>ASA-induced asthma is an uncommon but very important indication of ASA and NSAID sensitivity. It occurs more frequently in patients with asthma who have nasal polyps.</p><p>&nbsp;</p><p><u>Sexual Function/Reproduction</u></p><p>The use of Naproxen, as with any drug known to inhibit cyclooxygenase/ prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. Therefore, in women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of Naproxen should be considered.</p><p>&nbsp;</p><p><u>Skin</u></p><p>In rare cases, serious skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis and erythema multiforme have been associated with the use of some NSAIDs. Because the rate of these reactions is low, they have usually been noted during post-marketing surveillance in patients taking other medications also associated with the potential development of these serious skin reactions. Thus, causality is NOT clear. These reactions are potentially life threatening but may be reversible if the causative agent is discontinued and appropriate treatment instituted. Patients should be advised that if they experience a skin rash they should discontinue their NSAID and contact their physician for assessment and advice, including which additional therapies to discontinue.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p>&nbsp;</p><p><strong><em>Pregnant</em></strong><strong><em> Women: </em></strong><strong>Naproxen</strong><strong> is CONTRAINDICATED for use during the third trimester of pregnancy because of risk of premature closure of the ductus arteriosus and the potential to prolong parturition (see TOXICOLOGY).</strong></p><p><strong>Caution</strong><strong> should be exercised in prescribing Naproxen during the first and second trimesters of pregnancy (see TOXICOLOGY).</strong></p><p>Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or the embryo-foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy.</p><p>In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.</p><p>Naproxen is not recommended in labour and delivery because, through their prostaglandin synthesis inhibitory effect, they may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage.</p><p><em>Nursing Women: </em>(See CONTRAINDICATIONS)</p><p><em>Pediatrics: </em><strong>(</strong>See CONTRAINDICATIONS<strong>)</strong></p><p><em>Geriatrics: </em>Patients older than 65 years and frail or debilitated patients are more susceptible to a variety of adverse reactions from non-steroidal anti-inflammatory drugs (NSAIDs): the incidence of these adverse reactions increases with dose and duration of treatment. &nbsp;In addition, these patients are less tolerant to ulceration and bleeding.&nbsp; Most reports of fatal GI events are in this population.&nbsp; Older patients are also at risk of lower esophageal ulceration and bleeding.</p><p>For such patients, consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision. See &ldquo;PRECAUTIONS&rdquo; for further advice.</p><p>&nbsp;</p><p><u>Monitoring and Laboratory Tests</u></p><p>Patients on long-term treatment with Naproxen should have their blood pressure monitored regularly and an ophthalmic examination should be carried out at periodic intervals (See WARNINGS AND PRECAUTIONS: Cardiovascular and Ophthalmic).</p><p>Hemoglobin, hematocrit, red blood cells (RBCs), white blood cells (WBCs), and platelets should be checked in patients on long-term treatment with Naproxen. Additionally, concurrent therapy with warfarin requires close monitoring of the international normalized ratio (INR) (See WARNINGS AND PRECAUTIONS: Hematology).</p><p>Serum transaminase and bilirubin should be monitored regularly during Naproxen therapy (see WARNINGS AND PRECAUTIONS: Hepatic, Biliary, Pancreatic).</p><p>Serum creatinine, creatine clearance and serum urea should be checked in patient during Naproxen therapy. Electrolytes including serum potassium should be monitored periodically (see WARNINGS AND PRECAUTIONS: Renal).</p><p>Monitoring of plasma lithium concentration is recommended when stopping or starting Naproxen therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Acetylsalicylic acid (ASA) or other NSAIDs: </em>The use of Naproxen (naproxen) in addition to any other NSAID, including those over the counter ones (such as ASA and ibuprofen) is NOT recommended because of the absence of any evidence demonstrating synergistic benefits and the possibility of additive adverse reactions.</p><p>The exception is the use of low dose ASA for cardiovascular protection, when another NSAID is being used for its analgesic/anti-inflammatory effect, keeping in mind that combination NSAID therapy is associated with additive adverse reactions.</p><p>Some NSAIDs (e.g. ibuprofen) may interfere with the anti-platelet effects of low dose ASA, possibly by competing with ASA for access to the active site of cyclooxygenase-1.</p><p><em>Albumin-bound</em><em> Drugs: &nbsp;</em>The naproxen anion may displace from their binding sites other drugs which are also albumin&ndash;bound and may lead to drug interactions.&nbsp; For example, in patients receiving bishydroxycoumarin or warfarin, the addition of Naproxen to therapy could prolong the prothrombin time. These patients should therefore be under careful observation. Similarly, patients receiving Naproxen and a hydantoin, sulfonamide, or sulfonylurea should be observed for adjustments of dose if required.</p><p><em>Antacids: </em>The rate of absorption of naproxen is altered by concomitant administration of antacids but is not adversely influenced by the presence of food.</p><p><em>Antic-coagulants:</em><em> </em>(See WARNINGS AND PRECAUTIONS: Hematologic, Anticoagulants)</p><p><em>Anti-hypertensives: </em>NSAIDs may diminish the anti-hypertensive effect of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).</p><p>Concomitant use of NSAIDs with ACE inhibitors or angiotensin receptor blockers may increase the risk of renal dysfunction, especially in patients with pre-existing poor renal function (see WARNINGS AND PRECAUTIONS: Renal).</p><p>Combinations of ACE inhibitors, angiotensin-II antagonists, or diuretics with NSAIDs might have an increased risk for acute renal failure and hyperkalemia. Blood pressure and renal function (including electrolytes) should be monitored more closely in this situation, as occasionally there can be a substantial increase in blood pressure.</p><p>Naproxen and other non-steroidal anti-inflammatory drugs can reduce the antihypertensive effect of propranolol and other beta-blockers as well as other antihypertensive agents.</p><p><em>Anti-platelet Agents (including ASA): </em>There is an increased risk of bleeding, via inhibition of platelet function, when anti-platelet agents are combined with NSAIDs, such as Naproxen.(see WARNINGS AND PRECAUTIONS: Hematologic, Anti-platelet Effects)</p><p><em>Cyclosporine:</em><em> </em>Inhibition of renal prostaglandin activity by NSAID&rsquo;s may increase the plasma concentration of cyclosporine and/or the risk of cyclosporine induced nephrotoxicity. Patients should be carefully monitored during concurrent use.</p><p><em>Cholestyramine</em>:&nbsp; Concomitant administration of cholestyramine can delay the absorption of naproxen, but does not affect its extent.</p><p><em>Digoxin: </em>Concomitant administration of an NSAID with digoxin can result in an increase in digoxin concentration which may result in digitalis toxicity. &nbsp;Increased monitoring and dosage adjustments of digitalis glycosides may be necessary during and following concurrent NSAID therapy.</p><p><em>Diuretics: </em>The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class.</p><p><em>Glucocorticoids: </em>Numerous studies have shown that the concomitant use of NSAIDs and oral glucocorticoids increases the risk of GI side effects such as ulceration and bleeding.&nbsp; This is especially the case in older (&gt;65 years of age) individuals.</p><p><em>Lithium: &nbsp;</em>Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.</p><p><em>Methotrexate: </em>Caution is advised in the concomitant administration of naproxen and methotrexate since naproxen and other non-steroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, thereby possibly enhancing its toxicity.</p><p><em>Probenecid:</em><em> </em>Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half&ndash;life significantly.</p><p><em>Selective </em><em>Serotonin Reuptake Inhibitors (SSRIs): </em>Concomitant administration of NSAIDs and SSRIs may increase the risk of gastrointestinal ulceration and bleeding (see WARNINGS AND PRECAUTIONS: Gastrointestinal).</p><p>&nbsp;</p><p><strong><u>Drug-Food Interactions</u></strong></p><p>Concomitant administration of food can delay the absorption of naproxen, but does not affect its extent.</p><p>&nbsp;</p><p><strong><u>Drug-Herb Interactions</u></strong></p><p>Interactions with herbal products have not been established.</p><p>&nbsp;</p><p><strong><u>Drug-Laboratory Interactions</u></strong></p><p>Interactions with laboratory tests have not been established.</p><p>&nbsp;</p><p><strong><u>Drug-Lifestyle Interactions</u></strong></p><p>There are no specific studies about effects on the ability to drive vehicles and to use machinery. Patients who experience visual disturbances or other central nervous system disturbances should refrain from these activities.</p><p>Concurrent use of alcohol with an NSAID may increase the risk of gastrointestinal side effects, including ulceration and hemorrhage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects</strong><strong> on Fertility</strong></p><p>The use of Naproxen, as with any drug known to inhibit cyclooxygenase/ prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive.</p><p>Therefore, in women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of Naproxen should be considered.</p><p>&nbsp;</p><p><strong>Use in Pregnancy (Category C)</strong></p><p>It is contraindicated in the third trimester of pregnancy, because of risk of premature closure of the ductus arteriosus and prolonged parturition women who are breastfeeding, because of the potential for serious adverse reactions in nursing infants.</p><p>&nbsp;</p><p><strong>Use in Lactation</strong></p><p>Daily oral administration of 15, 30 or 60 mg/kg of naproxen to female rabbits from 2 weeks before mating until day 20 of pregnancy did not affect fertility, gestation, or the numbers of live fetuses.</p><p>In a peri- and post-natal study in rats, oral doses of naproxen up to 20 mg/kg administered daily during the last part of pregnancy through weaning did not result in adverse effects in viability of pups, lactation index, sex ratio, or weight gain of offspring. However, there was a slight increase in gestation length at the 10 and 20 mg/kg dose levels; and at the 10 mg/kg dose level, there was a significant increase in stillbirths.</p><p>Naproxen at daily oral doses of 12, 36 or 108 mg/kg to female mice from 2 weeks before mating until weaning of the pups did not cause changes in length of gestation, number of pups born, average pup weight at 0, 4, 7, 14 or 21 days, or sex distribution. The fertility index, gestation index, and 4-day viability index were similar for mice from the control and treated groups.&nbsp; The 21-day survival and lactation indexes were decreased for mice from the group fed 108 mg/kg/day of naproxen, but not for mice given 12 or 36 mg/kg/day. Most of this change was due to maternal mortality in the high dose group.</p><p>Recent evidence suggests that inhibition of prostaglandin synthesis by non-steroidal anti- inflammatory compounds may be related to decreased uterine contractibility. &nbsp;Thus, the onset of labor in a rat model system can be delayed with naproxen administration without causing maternal or fetal deaths in excess of that seen in controls. Since it has been shown that naproxen inhibits prostaglandin synthesis <u>in vitro</u>, it has been suggested that the effects of naproxen on uterine contractility are mediated through that mechanism.</p><p>Maternal and fetal deaths seen in naproxen-treated rats were, therefore, apparently related to dystocia rather than to a direct toxic effect of the compound. Naproxen is not unique in this regard, since comparable results were obtained in the rat with other commonly used non- steroidal anti-inflammatory agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no specific studies about effects on the ability to drive vehicles and to use machinery.</p><p>Patients who experience visual disturbances or other central nervous system disturbances should refrain from these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adverse </strong><strong>Drug Reaction Overview</strong></p><p>The most common adverse reactions encountered with nonsteroidal anti-inflammatory drugs are gastrointestinal, of which peptic ulcer, with or without bleeding, is the most severe. Fatalities have occurred particularly in the elderly.</p><p>As with all drugs in this class, the frequency and severity of adverse events depends on several factors: the dose of the drug and duration of treatment; the age, the sex, physical condition of the patient; any concurrent medical diagnoses or individual risk factors.</p><p>&nbsp;</p><p><strong>Clinical Trial Adverse Drug Reactions</strong></p><p>A clinical study found gastrointestinal reactions to be more frequent and more severe in rheumatoid arthritis patients taking daily doses of 1500 mg naproxen compared to those taking 750 mg naproxen.</p><p>The adverse reactions in controlled clinical trials in 960 patients with rheumatoid arthritis or osteoarthritis treated with the Naproxen standard tablets are listed below.</p><table border="1" cellspacing="0" cellpadding="0"><caption><p style="text-align:left"><strong>Table 1: Most Common Clinical Trial Adverse Drug Reactions (3%-9% and 1%-3%)</strong></p></caption><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong></p></td><td style="vertical-align:top"><p><strong>Incidence</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>Gastrointestinal</p></td><td style="vertical-align:top"><p><u>3%-9%</u></p></td><td style="vertical-align:top"><p>Heartburn, constipation, abdominal pain, nausea</p></td></tr><tr><td style="vertical-align:top"><p><u>1%-3%</u></p></td><td style="vertical-align:top"><p>Diarrhea, dyspepsia,&nbsp; stomatitis, diverticulitis, gastrointestinal bleeding</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>Central Nervous System</p></td><td style="vertical-align:top"><p><u>3%-9%</u></p></td><td style="vertical-align:top"><p>Headache, dizziness, drowsiness</p></td></tr><tr><td style="vertical-align:top"><p><u>1%-3%</u></p></td><td style="vertical-align:top"><p>Light-headedness, vertigo, depression, fatigue. Occasionally patients had to discontinue treatment because of the severity of some of these complaints (headache and dizziness).</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>Dermatologic</p></td><td style="vertical-align:top"><p><u>3%-9%</u></p></td><td style="vertical-align:top"><p>Pruritus, ecchymoses, skin eruptions</p></td></tr><tr><td style="vertical-align:top"><p><u>1%-3%</u></p></td><td style="vertical-align:top"><p>Sweating, purpura</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>Cardiovascular</p></td><td style="vertical-align:top"><p><u>3%-9%</u></p></td><td style="vertical-align:top"><p>Dyspnea, peripheral edema</p></td></tr><tr><td style="vertical-align:top"><p><u>1%-3%</u></p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>Special Senses</p></td><td style="vertical-align:top"><p><u>3%-9%</u></p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><u>1%-3%</u></p></td><td style="vertical-align:top"><p>Hearing disturbances</p></td></tr><tr><td style="vertical-align:top"><p>General</p></td><td style="vertical-align:top"><p><u>1%-3%</u></p></td><td style="vertical-align:top"><p>Thirst</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><caption><p style="text-align:left"><strong>Table 2: Less Common Clinical Trial Adverse Drug Reactions (&lt;1%)</strong></p></caption><tbody><tr><td style="vertical-align:top" rowspan="1"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top"><p>Bleeding, hematemesis, melena, peptic ulceration &nbsp;with or without bleeding and/or perforation, vomiting, ulcerative stomatitis.</p></td></tr><tr><td style="vertical-align:top" rowspan="1"><p><strong>System</strong></p></td><td style="vertical-align:top"><p>Inability to concentrate, malaise, myalgia, insomnia and cognitive dysfunction (i.e. decreased attention span, loss of short-term memory, difficulty with calculations).</p></td></tr><tr><td style="vertical-align:top" rowspan="1"><p><strong>Dermatologic</strong></p></td><td style="vertical-align:top"><p>Alopecia, urticaria, skin rash, erythema multiforme, Stevens-Johnson syndrome, epidermal necrolysis, photosensitive dermatitis, exfoliative dermatitis, erythema nodosum.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatic</strong></p></td><td style="vertical-align:top"><p>Abnormal liver function tests, jaundice, cholestasis and hepatitis. congestive heart failure and vasculitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiovascular</strong></p></td><td style="vertical-align:top"><p>Congestive heart failure and vasculitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal</strong></p></td><td style="vertical-align:top"><p>Glomerular nephritis, hematuria, interstitial nephritis, nephrotic syndrome, nephropathy and tubular necrosis.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hematologic</strong></p></td><td style="vertical-align:top"><p>Eosinophilia, granulocytopenia, leukopenia, thrombocytopenia, agranulocytosis, aplastic anemia and hemolytic anemia.</p></td></tr><tr><td style="vertical-align:top" rowspan="1"><p><strong>Special Senses</strong></p></td><td style="vertical-align:top"><p>Hearing impairment and visual disturbances.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive</strong></p></td><td style="vertical-align:top"><p>Female infertility</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong></p></td><td style="vertical-align:top"><p>Muscle weakness, anaphylactoid reactions, menstrual disorders,pyrexia (chills and fever), angioneurotic edema, hyperglycemia,hypoglycemia and eosinophilic pneumonitis.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>The following additional adverse events have been reported with NSAIDs including naproxen and naproxen sodium:</p><p><strong>Gastrointestinal:&nbsp;</strong>Inflammation, bleeding (sometimes fatal, particularly in the elderly), ulceration, perforation and obstruction of the upper or lower gastrointestinal tract. Oesophagitis, gastritis, pancreatitis, stomatitis. Exacerbation of ulcerative colitis and Crohn&rsquo;s disease. Heartburn, dyspepsia, abdominal pain, nausea, vomiting, diarrhoea, flatulence, constipation, haematemesis, melaena.</p><p><strong>Infections:&nbsp;</strong>aseptic meningitis</p><p><strong>Blood and Lymphatic System Disorders:</strong>&nbsp;agranulocytosis, aplastic anaemia, eosinophilia, haemolytic anaemia, leucopoenia, thrombocytopenia</p><p><strong>Immune System Disorders :&nbsp;</strong>anaphylactoid reactions</p><p><strong>Metabolic and Nutrition Disorders:&nbsp;</strong>hyperkalemia</p><p><strong>Psychiatric Disorders:&nbsp;</strong>depression, dream abnormalities, insomnia</p><p><strong>Nervous System:&nbsp;</strong>dizziness, drowsiness, headache, lightheadedness, retrobulbar optic neuritis convulsions, cognitive dysfunction, inability to concentrate</p><p><strong>Eye Disorders:&nbsp;</strong>visual disturbances, corneal opacity, papillitis, papilloedema</p><p><strong>Ear and Labyrinth&nbsp;Disorders:&nbsp;</strong>hearing impairment, hearing disturbances, tinnitus, vertigo</p><p><strong>Cardiac Disorders:&nbsp;</strong>&nbsp;palpitations, cardiac failure has been reported in association with NSAID treatment, congestive heart failure</p><p><strong>Vascular<strong> </strong>Disorders:&nbsp;</strong>Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke)</p><p><strong>Respiratory,</strong><strong> </strong><strong>Thoracic and Mediastinal Disorders:&nbsp;</strong>dyspnoea, pulmonary oedema, asthma, eosinophilic pneumonitis.</p><p><strong>Hepatobiliary<strong> </strong>Disorders:&nbsp;</strong>hepatitis (some cases of hepatitis have been fatal), jaundice.</p><p><strong>Skin and Subcutaneous Tissue Disorders:&nbsp;</strong>&nbsp;ecchymoses, itching (pruritus), purpura, skin eruptions, sweating,alopecia, epidermal necrolysis, very rarely toxic epidermal necrolysis, erythema multiforme, bullous reactions, including Stevens-Johnson syndrome, erythema nodosum, fixed drug eruption, lichen planus, pustular reaction, skin rashes, SLE, urticaria, photosensitivity reactions, including rare cases resembling porphyria cutanea tarda (&ldquo;pseudoporphyria&rdquo;) or epidermolysis bullosa and angioneurotic oedema.</p><p>If skin fragility, blistering or other symptoms suggestive of pseudoporphyria occur, treatment should be discontinued and the patient monitored.</p><p><strong>Musculoskeletal<strong> </strong>and Connective Tissue Disorders:&nbsp;</strong>myalgia, muscle weakness.</p><p><strong>Renal and Urinary Disorders:&nbsp;</strong>haematuria, interstitial nephritis, nephrotic syndrome, renal disease, renal failure, renal papillary necrosis</p><p><strong>Reproductive System and Breast Disorders:&nbsp;</strong>&nbsp;female infertility</p><p><strong>General Disorders and Administration Site Conditions:&nbsp;</strong>oedema, thirst, pyrexia (chills and fever), malaise</p><p><strong>Investigations:&nbsp;</strong>abnormal liver function tests, raised serum creatinine</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p style="text-align:center"><strong>For management of a suspected drug overdose, contact your regional Poison Control Centre.</strong></p></td></tr></tbody></table><p><strong><u>Symptoms and Signs</u></strong></p><p>Significant overdosage may be characterized by drowsiness, dizziness, disorientation, heartburn, indigestion, epigastric pain, abdominal discomfort, nausea, vomiting, transient alterations in liver function, hypoprothrombinemia, renal dysfunction, metabolic acidosis and apnea.&nbsp; A few patients have experienced convulsions, but it is not clear whether or not these were naproxen related.</p><p>Gastrointestinal bleeding may occur. Hypertension, acute renal failure, respiratory depression and coma may occur after the ingestion of NSAIDs but are rare.</p><p>Anaphylactoid reactions have been repeated with therapeutic ingestion of NSAIDs, and may occur following an overdose.</p><p>&nbsp;</p><p><strong><u>Treatment</u></strong></p><p>Patients should be managed by symptomatic and supportive care following NSAIDs overdose. There are no specific antidotes. Prevention of further absorption (e.g. activated charcoal) may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose. Forced diuresis, alkalinization of urine, haemodialysis, or haemoperfusion may not be useful due to high protein binding.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Mechanism</u></strong><strong><u> </u></strong><strong><u>of Action</u></strong></p><p>Naproxen contains naproxen, a member of the arylacetic acid group of NSAIDs.</p><p>Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic properties. The mechanism of action of naproxen, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition. During clinical trials, naproxen has been found to be less likely to cause gastrointestinal bleeding in doses usually used than is acetylsalicylic acid.</p><p>Naproxen has been shown to possess marked anti-inflammatory, analgesic and antipyretic activity, as assessed by a variety of animal test procedures.</p><p>&nbsp;</p><p><strong>Anti-inflammatory activity: </strong>In the rat paw edema assay, naproxen was more potent than phenylbutazone and acetylsalicylic acid and slightly less potent than indomethacin.</p><p>In the rat granuloma assay, naproxen was more active than phenylbutazone, and less active than indomethacin.</p><p>&nbsp;</p><p><strong>Analgesic activity: </strong>In a mouse analgesic assay using phenylquinone for pain induction, naproxen was more active than phenylbutazone and acetylsalicylic acid, and less active than indomethacin.&nbsp; Parallel comparative analgesic studies were done in rats with yeast-induced paw edema.</p><p>In these assays, naproxen had a higher relative potency than phenylbutazone and acetylsalicylic acid, but lower relative potency when compared to indomethacin.</p><p>The comparative absorption, distribution, metabolism, and excretion of naproxen were studied in several species, including man. Naproxen was found to be rapidly absorbed in all species and, once in the blood, was eliminated with half-lives ranging from 2 to 35 hours.&nbsp; Estimated volumes of distribution indicated that a large fraction of the drug is held in the blood, much like salicylates are.&nbsp; Virtually all of the drug present in the blood of humans was determined to be unchanged naproxen, while the rat and monkey showed minor amounts of transformation products.&nbsp; With the exception of the dog, all species excreted naproxen and its metabolic transformation products predominantly in the urine. &nbsp;In the dog, the preferred route was fecal.</p><p>Studies by Tomlinson et al, have shown that naproxen can inhibit the synthesis of prostaglandin E2&nbsp;from arachidonic acid by bovine seminal vesical microsomes. Naproxen therefore appears to act, at least in part, in a manner similar to other anti-inflammatory agents which block prostaglandin biosynthesis.</p><p>&nbsp;</p><p><strong><u>Human metabolic studies</u>:</strong></p><p>The plasma-level response to oral naproxen doses ranging up to 900 mg twice daily was studied in normal subjects.&nbsp; Experiments with tritium-labelled naproxen showed that there was no difference in the fraction of ingested drug excreted in the stools whether the dose was 250 mg or 900 mg, thus eliminating the possibility that this effect was a result of incomplete absorption.</p><p>Accelerated renal clearance at high doses because of disproportionate increases in the amount of unbound drug appeared to be the most likely explanation for the plateau effect.</p><p>In patients treated with maintenance dialysis for terminal renal failure, serum level studies indicated that the metabolite 6-0-desmethyl naproxen is dialysed, whilst naproxen is not.&nbsp; No accumulation of naproxen was found although serum levels of the metabolite increased.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Naproxen is rapidly and completely absorbed from the gastrointestinal tract. After administration of naproxen, peak plasma levels of naproxen anion are attained in 2 to 4 hours, with steady-state conditions normally achieved after 4-5 doses. Plasma naproxen levels and areas under plasma concentration vs. time curves increased linearly with dose increments up to 500 mg twice a day, but larger doses resulted in a plateau effect.&nbsp; The mean biological half-life of the anion in humans is approximately 13 hours, and at therapeutic levels it is greater than 99% albumin bound.</p><p>Approximately 95% of the dose is excreted in the urine, primarily as naproxen, 6-0-desmethyl naproxen or their conjugates.&nbsp; The rate of excretion has been found to coincide closely with the rate of drug disappearance from the plasma. The drug does not induce metabolizing enzymes. When naproxen is administered in the sustained-release form, the peak plasma levels are delayed and the maximum plasma concentrations are reduced compared to those seen with standard release formulations of naproxen.&nbsp; The minimum plasma concentrations, at steady state, are equivalent between the sustained-release form of naproxen given once a day and the corresponding standard dosage given twice a day. &nbsp;The peak to trough plasma concentration ratio of 2.2 and 2.6 observed with the standard tablet formulation (375 mg b.i.d. and 500 mg b.i.d. respectively) is reduced to 1.6 and 1.8 with the 750 and 1000 mg sustained-release naproxen tablets respectively, resulting in smaller fluctuations in plasma concentrations of naproxen with the sustained-release naproxen tablets.</p><p>The average Tmax&nbsp;of naproxen in subjects receiving the 1000 mg sustained-release tablet immediately after a high-fat meal did not differ significantly when compared to the fasting state (7.7 hours post-prandial; 9.7 hours fasting). The average Cmax&nbsp;increased significantly from 63.1</p><p>mg/mL (fasting) to 86.1 mg/mL (post-prandial). &nbsp;This increase in Cmax&nbsp;was still lower than that observed with the 1000 mg dose of standard naproxen tablets. Based upon the 95% confidence interval, the AUCs were equivalent when the SR tablet was administered under fasting and non- fasting conditions.</p><p>A 28 day study of chromium labeled red blood cell loss in feces was conducted with the 750 mg sustained-release naproxen tablets in 20 patients.&nbsp; There was no statistically significant difference in red blood cell loss between patients 60 years of age or younger and those over 60. Enteric-coated naproxen is designed to be dispersed and dissolved in the small bowel rather than the stomach, so the absorption is delayed until the stomach is emptied.&nbsp; Naproxen enteric-coated tablets were bioequivalent to the standard 375 mg and 500 mg tablets, except for a substantially increased time to peak plasma concentration (Tmax). The average maximum plasma concentration (Cmax) following the 375 mg, 2 x 250 mg and 500 mg enteric-coated tablets were 47.9, 58.2 and 60.7 &micro;g/mL, while the Cmax&nbsp;following the 375 mg and 500 mg standard immediate release tablets were 46.6 and 63.1 &micro;g/mL respectively. The Tmax&rsquo;s were 4.5, 4.2 and 4.2 hours for the respective enteric-coated formulations, as compared to 2.3 and 2.6 hours after standard naproxen tablets. At steady state (multiple dosing) enteric-coated naproxen and standard naproxen were equivalent to each other with respect to Cmax, Cave, Cmax/Cave, 0-12 hours AUC and half-life. &nbsp;In addition, fluctuations in plasma levels about Cave&nbsp;were considerably less with naproxen enteric-coated tablets as compared to standard naproxen (49.3% vs. 85.3%).</p><p>Administration of 500 mg enteric-coated naproxen tablets with food and antacid did not alter the extent of absorption of naproxen as compared to the fasting condition.&nbsp; However, antacid treatment resulted in a higher Cmax&nbsp;(70.7 vs. 58.5 &micro;g/mL) and earlier Tmax (5.2 vs. 8.7 hours) in comparison to the fasting condition.&nbsp; Relative to the fasting state, the average Tmax&nbsp;was delayed following a high fat meal (5.6 &ndash; 8.7 hours fasting, 9.2 &ndash; 10.8 hours post prandial) while the average Cmax&nbsp;and AUC were bioequivalent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Acute Animal Toxicity</u></strong></p><p>The oral LD50&nbsp;values for naproxen are as follows:</p><p>Hamsters:&nbsp; 4110 mg/kg</p><p>Rats: 543 mg/kg</p><p>Dogs: &gt; 1000 mg/kg Mice: 1234 mg/kg</p><p>&nbsp;</p><p><strong><u>Subacute and Chronic Oral Toxicity</u></strong></p><p>In subacute and chronic oral studies with naproxen in a variety of species, the principal pathologic effect was gastrointestinal irritation and ulceration. The lesions seen were predominantly in the small intestine and ranged from hyperemia to perforation and peritonitis. Nephropathy was seen occasionally in rats, mice, and rabbits at high-dose levels of naproxen, but not in rhesus monkeys or miniature pigs. &nbsp;In the affected species, the pathologic changes occurred in the cortex and papilla. Some rats examined 14 days after single oral doses of 230 mg/kg or more of naproxen evidenced necrotic areas of cortical and papillary tissue.&nbsp; Tubular dilation (ectasia) occurred in rabbits dosed orally for 14 days with 200 mg/kg/day or more of naproxen. An examination of unfixed renal tissue from rabbits so treated was conducted and revealed the presence of diffraction patterns similar to that of crystalline naproxen. This suggests that the ectasia observed was a physical response to deposition of excreted naproxen within the tubules.</p><p>In mice given oral doses of 120 mg/kg/day or more of naproxen for 6 months, the kidneys were characterized by a low, but non-dosage-related incidence of cortical sclerosis and papillary tip necrosis.&nbsp; Chronic administration of high doses of naproxen to mice appears to be associated with exacerbation of spontaneous murine nephropathy.</p><p>A wide variation in susceptibility to gastrointestinal lesions from administration of naproxen was evident in the various species tested.&nbsp; For example, 30 mg/kg/day was tolerated well by rats for 90 days, but the same dose was ulcerogenic when administered for 6 months. Rhesus monkeys and miniature swine exhibited no significant pathology when dosed with naproxen at 45 mg/kg/day for 30 days. &nbsp;This dose of naproxen was also tolerated by miniature swine without obvious evidence of adverse effects when administered daily for one year. &nbsp;In rhesus monkeys, doses as high as 120 mg/kg/day administered b.i.d. for 6 months produced no clinical or histopathological evidence of gastrointestinal irritation although occult blood in the feces occurred more frequently in these animals as compared to controls. &nbsp;In rabbits, the maximum tolerated repeated oral dose is 200 mg/kg/day. Mice tolerated oral daily doses of 240 mg/kg/day for 6 months. &nbsp;In both rabbits and mice, gastrointestinal and renal toxicity was reported at these dose levels. &nbsp;In dogs, on the other hand, 5.0 mg/kg/day approaches the maximum tolerated dose. This peculiar canine susceptibility to gastrointestinal effects of non-steroidal anti-inflammatory agents has also been shown with indomethacin and ibuprofen.</p><p>In dogs, naproxen exhibits a considerably longer plasma half-life than it does in rats, guinea pigs, miniature swine, monkeys and man. The same observation has been made with ibuprofen in dogs compared to rats and man. &nbsp;In addition, in the species listed, only the dog excretes significant amounts of administered naproxen in the feces (50%). &nbsp;In the rat, guinea pigs, miniature swine, monkeys, and man, 86-94% of the administered drug is excreted in the urine.</p><p>The suggested enterohepatic circulation of naproxen in the dog (as judged by the fecal excretion) may be a major factor in the susceptibility of the dog to gastrointestinal irritation by this compound.</p><p>Pathologic changes in the spleen and mesenteric lymph nodes as well as peritoneal inflammation and adhesions were considered to be clearly secondary to the effects of high doses of naproxen on the gastrointestinal tract.&nbsp; Moderate weight loss of the male secondary sex glands occurred in some studies in naproxen-treated rats and dogs. Histopathologically, the affected glands in some instances exhibited atrophic and/or hypoplastic changes characterized by decreased secretory material.&nbsp; A possible estrogenic action of naproxen as a causative factor seems highly unlikely since in standard bioassay procedures, the drug exhibited no estrogenic activity.</p><p>Nevertheless, daily doses of naproxen as high as 30 mg/kg administered for 60 days before mating had no effect on fertility and reproductive performance of male rats. These results reflect the physiological integrity of the entire male reproductive apparatus after administration of naproxen throughout the spermatogenic cycle.</p><p>&nbsp;</p><p><strong><u>Effect on Induced Infections in Rabbits</u></strong></p><p>To determine whether treatment with naproxen affects the ability of animals to respond to bacterial infection, rabbits were inoculated subcutaneously with <em>Diplococcus pneumoniae</em>.&nbsp; For 21 days before bacterial challenge and during a 2-week post-challenge period the animals were dosed daily by gavage with 2, 10, or 20 mg/kg of naproxen. Clinical conditions, morbidity, mortality, gross and histopathologic changes were evaluated.&nbsp; There were no apparent effects of naproxen in altering the response of the animals to bacterial challenge.</p><p>&nbsp;</p><p><strong><u>Teratology</u></strong></p><p>In teratology studies, no skeletal or visceral anomalies or pathologic changes were induced in the fetuses of pregnant rats and rabbits treated during organogenesis with daily oral doses of naproxen up to 20 mg/kg. &nbsp;In these studies, there were also no significant differences from controls in the number of live fetuses, resorptions, fetal weights or ano-genital distances.</p><p>&nbsp;</p><p><strong><u>Reproductive Studies</u></strong></p><p>Daily oral administration of 15, 30 or 60 mg/kg of naproxen to female rabbits from 2 weeks before mating until day 20 of pregnancy did not affect fertility, gestation, or the numbers of live fetuses.</p><p>In a peri- and post-natal study in rats, oral doses of naproxen up to 20 mg/kg administered daily during the last part of pregnancy through weaning did not result in adverse effects in viability of pups, lactation index, sex ratio, or weight gain of offspring. However, there was a slight increase in gestation length at the 10 and 20 mg/kg dose levels; and at the 10 mg/kg dose level, there was a significant increase in stillbirths.</p><p>Naproxen at daily oral doses of 12, 36 or 108 mg/kg to female mice from 2 weeks before mating until weaning of the pups did not cause changes in length of gestation, number of pups born, average pup weight at 0, 4, 7, 14 or 21 days, or sex distribution. The fertility index, gestation index, and 4-day viability index were similar for mice from the control and treated groups.&nbsp; The 21-day survival and lactation indexes were decreased for mice from the group fed 108 mg/kg/day of naproxen, but not for mice given 12 or 36 mg/kg/day. Most of this change was due to maternal mortality in the high dose group.</p><p>Recent evidence suggests that inhibition of prostaglandin synthesis by non-steroidal anti- inflammatory compounds may be related to decreased uterine contractibility. &nbsp;Thus, the onset of labor in a rat model system can be delayed with naproxen administration without causing maternal or fetal deaths in excess of that seen in controls. Since it has been shown that naproxen inhibits prostaglandin synthesis <u>in vitro</u>, it has been suggested that the effects of naproxen on uterine contractility are mediated through that mechanism.</p><p>Maternal and fetal deaths seen in naproxen-treated rats were, therefore, apparently related to dystocia rather than to a direct toxic effect of the compound. Naproxen is not unique in this regard, since comparable results were obtained in the rat with other commonly used non- steroidal anti-inflammatory agents.</p><p>&nbsp;</p><p><strong><u>Carcinogenicity</u></strong></p><p>Naproxen was administered with food to Sprague-Dawley rats for 24 months at doses of 8,16 and 24 mg/kg/day. naproxen was not carcinogenic in rats.</p><p>&nbsp;</p><p><strong><u>Mutagenicity</u></strong></p><p>Mutagenicity was not seen in <em>Salmonella typhimurium </em>(5 cell lines), <em>Sachharomyces cerevisisae</em></p><p>(1 cell line), and mouse lymphoma tests.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methylcellulose</p></td></tr><tr><td style="vertical-align:top"><p>Croscarmellose sodium</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium stearate</p></td></tr><tr><td style="vertical-align:top"><p>Colloidal silicon dioxide</p></td></tr><tr><td style="vertical-align:top"><p>D&amp;C yellow #10</p></td></tr><tr><td style="vertical-align:top"><p>FD&amp;C yellow #6</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C and keep out of reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Strength</p></td><td style="vertical-align:top"><p>Unit Count or Fill Size</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Container Size(s)</p></td><td style="vertical-align:top"><p>Description</p></td></tr><tr><td style="vertical-align:top"><p>250 mg</p></td><td style="vertical-align:top"><p>20&rsquo;s (2 x 10&rsquo;s)</p></td><td style="vertical-align:top"><p>Blister</p></td><td style="vertical-align:top" rowspan="2"><p>FILM PVC CLEAR 10 MIL 205MM FOIL SIVER PLAIN 205MM 25UM</p></td></tr><tr><td style="vertical-align:top"><p>500 mg</p></td><td style="vertical-align:top"><p>10&rsquo;s (1 x 10&rsquo;s)</p></td><td style="vertical-align:top"><p>Blister</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Secondary packaging:</strong></p><p>Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., 150 Signet Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>